Replies to post #169198 on Biotech Values

[DewDiligence]

Sofo pricing…equally for GT2 and GT3 would be very politically correct and GILD surely needs this kind of positive PR material, so they might do the gesture.

That could be accomplished by setting a ceiling on the cumulative price per patient, as Genentech once did for Avastin.